tiprankstipranks
Bionano Genomics launches OGM-based LDT for hematological malignancies
The Fly

Bionano Genomics launches OGM-based LDT for hematological malignancies

Bionano Laboratories announced the launch of OGM-Dx HemeOne, a laboratory developed test based on optical genome mapping analysis of blood or bone marrow samples to detect structural variants of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy. Compared to traditional cytogenetic methods, this OGM-based assay offers a streamlined and improved workflow to assess pathogenic SVs relevant to hematological malignancies including Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on BNGO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles